Ascendis Pharma A/S
ASND
166 hedge funds and large institutions have $9.25B invested in Ascendis Pharma A/S in 2021 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 74 increasing their positions, 48 reducing their positions, and 32 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 48
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
28% more capital invested
Capital invested by funds: $7.24B → $9.25B (+$2.01B)
0.43% more ownership
Funds ownership: 102.42% → 102.85% (+0.43%)
3% less funds holding
Funds holding: 171 → 166 (-5)
16% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 32
31% less call options, than puts
Call options by funds: $22.7M | Put options by funds: $33.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$186M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$137M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$79.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$69.9M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$45.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$105M |
| 2 |
O
OrbiMed
New York
|
-$58.9M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$49.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$38.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$30.9M |
ASND Hedge Fund Activity: Q3 2021 in Review
166 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q3 2021, worth a combined $9.25B — up 28% from $7.24B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of ASND and 27 opened new positions — a net loss of 5 holders — while 48 trimmed existing stakes and 74 added.
The largest buyer was Artisan Partners, adding an estimated $186M. The largest seller was Vivo Capital, cutting an estimated $105M.
- 166 institutional investors held Ascendis Pharma A/S (ASND) as of Q3 2021, down from 171 in Q2 2021.
- Funds reported $9.25B of Ascendis Pharma A/S stock for Q3 2021, up 28% quarter-over-quarter.
- 27 funds opened new Ascendis Pharma A/S positions in Q3 2021 and 32 closed out, a net change of -5 holders.
- The largest Ascendis Pharma A/S buyer in Q3 2021 was Artisan Partners, an estimated $186M added.
- The largest Ascendis Pharma A/S seller in Q3 2021 was Vivo Capital, an estimated $105M sold.
Based on aggregated 13F filings for Q3 2021.